AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26671622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCLs)
Number of subjects: 15
Study 26671622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ganciclovir 0.15% gel
Number of subjects: 15
Study 26671622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.4% povidone-iodine solution
Number of subjects: 15
Study 26671622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 15
Study 26671622 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free artificial tears and topical antibiotics
Number of subjects: 15
Study 24648018 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone session attendance
Number of subjects: 641
Study 22591726 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Number of subjects: 400
Study 22591726 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy plus radiotherapy (IC+RT)
Number of subjects: 400
Study 20528796 — intervention group
Group type: EXPERIMENTAL
Intervention: 500mL of 100% mandarin juice daily
Number of subjects: 40
Study 18760064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mueller‐Hinton agar with cefoxitin 30 microg disc
Number of subjects: 100
Study 18760064 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐sensitest agar with cefoxitin 30 microg disc
Number of subjects: 100
Study 15924512 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise and self-management program (10-week duration, conducted twice a week for one hour)
Number of subjects: 50
Study 15924512 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise and self-management program
Number of subjects: 50
Study 15924512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 12873574 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with food allergy
Number of subjects: 29
Study 12873574 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study 11045306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin application during the mupirocin period (group I)
Number of subjects: 42
Study 11045306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin application during the mupirocin period (group II)
Number of subjects: 42
Study 11045306 — intervention group
Group type: COMPARATOR
Intervention: Historical control data (group I before mupirocin application)
Number of subjects: 42
Study 8788291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lipase enteric-coated microsphere preparation
Number of subjects: 20
Study 8788291 — intervention group
Group type: COMPARATOR
Intervention: Low-lipase enteric-coated microsphere preparation
Number of subjects: 20
Study 1898640 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 34
Study 1898640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 6218815 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% (w/v) benzoyl peroxide gel
Number of subjects: 94
Study 6218815 — intervention group
Group type: COMPARATOR
Intervention: 1.5% (w/v) erythromycin lotion
Number of subjects: 94
Study 30366513 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology (PP) intervention
Number of subjects: 25
Study 30366513 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 25
Study 28948436 — intervention group
Group type: EXPERIMENTAL
Intervention: FAACT
Number of subjects: 96
Study 28948436 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-F
Number of subjects: 96
Study 28948436 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 96
Study 28948436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Outcome Index (TOI)
Number of subjects: 96
Study 29574075 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-APO(a)Rx
Number of subjects: 61
Study 29574075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 26631116 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone (PAN‐BTZ‐Dex)
Number of subjects: 825
Study 23225539 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (high-dose level)
Number of subjects: 0
Study 21858807 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals)
Number of subjects: 0
Study 20048654 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection ultrasound-guided infraclavicular block
Number of subjects: 88
Study 20048654 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-injection ultrasound-guided infraclavicular block
Number of subjects: 88
Study 20048654 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the single-injection group)
Number of subjects: 88
Study 16859992 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 75
Study 16859992 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 75
Study 15906589 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine formulation A (21 mg/day)
Number of subjects: 10
Study 15906589 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine formulation B (21 mg/day)
Number of subjects: 10
Study 15906589 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 12034157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization system (CRS) consisting of a pulse generator interfaced with an atrio-biventricular lead system.
Number of subjects: 103
Study 9861122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg i.v. followed by infusion at a rate of 90 mg/15.5 h
Number of subjects: 85
Study 9861122 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg followed by infusion of 75 mg/15.5 h
Number of subjects: 85
Study 9861122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg followed by infusion of 100 mg/15.5 h
Number of subjects: 85
Study 7542132 — intervention group
Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Score (IPSS)
Number of subjects: 502
Study 7542132 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSS
Number of subjects: 502
Study 2194687 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfamethoxazole + trimethoprim
Number of subjects: 614
Study 2194687 — intervention group
Group type: COMPARATOR
Intervention: procaine penicillin
Number of subjects: 614
Study 6173516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 20
Study 6173516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30768393 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Trigeminal Nerve Stimulation (TNS)
Number of subjects: 62
Study 30768393 — intervention group
Group type: COMPARATOR
Intervention: Sham Trigeminal Nerve Stimulation (TNS)
Number of subjects: 62
Study 28403832 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy group prenatal care (GPNC)
Number of subjects: 0
Study 28403832 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care (IPNC)
Number of subjects: 0
Study 25727941 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn silk aqueous extract (60, 130, 192.5 and 260 mg/kg body weight)
Number of subjects: 40
Study 25727941 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 40
Study 24773287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic exercise (4 × 4 min at 85% HRR and 2 min at 60% HRR) for 30 min
Number of subjects: 29
Study 24773287 — intervention group
Group type: COMPARATOR
Intervention: Moderate continuous aerobic exercise (70% HRR) for 30 min
Number of subjects: 29
Study 23077059 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (dlPFC) during a voluntary forgetting task
Number of subjects: 0
Study 23077059 — intervention group
Group type: COMPARATOR
Intervention: Cued to forget previously studied information
Number of subjects: 0
Study 19046326 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+CTG
Number of subjects: 85
Study 19046326 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 85
Study 17238221 — intervention group
Group type: EXPERIMENTAL
Intervention: Current drug treatment
Number of subjects: 0
Study 17238221 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative hypothetical drug
Number of subjects: 0
Study 17238221 — intervention group
Group type: EXPERIMENTAL
Intervention: No preventive medication
Number of subjects: 0
Study 16524633 — intervention group
Group type: EXPERIMENTAL
Intervention: DAHANCA toxicity scoring system
Number of subjects: 116
Study 16524633 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ
Number of subjects: 116
Study 14667152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bright light (approximately 5000 lux, 20 min on, 40 min off, 4‐5 light pulses/night)
Number of subjects: 67
Study 14667152 — intervention group
Group type: EXPERIMENTAL
Intervention: Darker sunglasses during daytime commute
Number of subjects: 67
Study 14667152 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1.8 mg sustained release)
Number of subjects: 67
Study 14667152 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sunglasses during daytime commute
Number of subjects: 67
Study 14667152 — intervention group
Group type: COMPARATOR
Intervention: Dim light (approximately 150 lux) during night shift
Number of subjects: 67
Study 14667152 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intermittent bright light, dark sunglasses, and regular early daytime dark/sleep period
Number of subjects: 67
Study 10612322 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin drug treatment
Number of subjects: 30817
Study 8777119 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 75
Study 8777119 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 75
Study 8777119 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 1647183 — intervention group
Group type: COMPARATOR
Intervention: vindesine plus cisplatin (VP)
Number of subjects: 126
Study 1647183 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin plus vindesine and cisplatin (MVP)
Number of subjects: 126
Study 6144522 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate 15 mg nocte
Number of subjects: 100
Study 6144522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg t.d.s.
Number of subjects: 100
Study 6144522 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 100
Study 29986721 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 0
Study 29986721 — intervention group
Group type: COMPARATOR
Intervention: Child safety control
Number of subjects: 0
Study 27484801 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy plus trastuzumab, lapatinib or both
Number of subjects: 121
Study 26162993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells (WJMSCs)
Number of subjects: 116
Study 26162993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 23412022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic slimming treatment (twice a day for 4 weeks)
Number of subjects: 0
Study 23412022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20303209 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed treatment with rigid maxillomandibular fixation
Number of subjects: 32
Study 20303209 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 32
Study 18343302 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 410
Study 18343302 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wire stabilization
Number of subjects: 410
Study 18343302 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plating with fixed-angle screws
Number of subjects: 410
Study 18343302 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture stabilization with locking volar plates
Number of subjects: 410
Study 18343302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pins and plaster, bone cement, open reduction and internal fixation with plates
Number of subjects: 410
Study 18343302 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-demand group
Number of subjects: 410
Study 15708387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin high dose (800 microg/kg) given three-monthly
Number of subjects: 0
Study 15708387 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin standard dose (150 microg/kg) given annually
Number of subjects: 0
Study 15708387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin high dose (800 microg/kg) given annually
Number of subjects: 0
Study 12906959 — intervention group
Group type: EXPERIMENTAL
Intervention: Two simultaneously consumed 400 microg OTFC doses
Number of subjects: 12
Study 12906959 — intervention group
Group type: COMPARATOR
Intervention: One 800 microg OTFC dose
Number of subjects: 12
Study 10543484 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HC), n = 14
Number of subjects: 29
Study 10543484 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuits (NHC), n = 15
Number of subjects: 29
Study 8912225 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline acid tartrate (0.33‐33.33 ng min‐1)
Number of subjects: 12
Study 8912225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose-response curve
Number of subjects: 12
Study 8912225 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncumulative dose-response curve
Number of subjects: 12
Study 8912225 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline application
Number of subjects: 12
Study 1841573 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 448
Study 1841573 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic studies (antinuclear antibody test, fluorescent treponemal antibody absorption test)
Number of subjects: 448
Study 1841573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest roentgenography
Number of subjects: 448
Study 1841573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Number of subjects: 448
Study 6354078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 85
Study 6354078 — intervention group
Group type: COMPARATOR
Intervention: Ceforanide
Number of subjects: 85
Study 31187261 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron picolinate (2.5 mg 57Fe per serving, two servings)
Number of subjects: 19
Study 31187261 — intervention group
Group type: COMPARATOR
Intervention: Iron sulfate (2.5 mg 54Fe per serving, two servings)
Number of subjects: 19
Study 31187261 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative bioavailability of Fe picolinate versus Fe sulfate
Number of subjects: 19
Study 30378695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpinia officinarum extract (300 mg daily for 3 months)
Number of subjects: 76
Study 30378695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 28431133 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 856
Study 28431133 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 856
Study 28431133 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 856
Study 26629352 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria <0.7 g/day after 12 months of treatment
Number of subjects: 90
Study 26629352 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of urine red blood cells <5/hpf as response criteria at month 12
Number of subjects: 90
Study 23703361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 110
Study 23703361 — intervention group
Group type: COMPARATOR
Intervention: Circular multipolar duty‐cycled radiofrequency-based pulmonary vein ablation catheter (PVAC)
Number of subjects: 110
Study 23703361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 21209240 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem XR for 5 days
Number of subjects: 0
Study 21209240 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem XR for 2 days
Number of subjects: 0
Study 21209240 — intervention group
Group type: COMPARATOR
Intervention: diltiazem CR for 2 days
Number of subjects: 0
Study 19747623 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Se Baker's yeast (300 microg/day)
Number of subjects: 42
Study 19747623 — intervention group
Group type: COMPARATOR
Intervention: Low-Se yeast
Number of subjects: 42
Study 17210735 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 10
Study 17210735 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 10
Study 15522771 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous task shift in RRMS patients
Number of subjects: 22
Study 15522771 — intervention group
Group type: COMPARATOR
Intervention: Non‐brain damaged controls (NBDC)
Number of subjects: 22
Study 10705194 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable impulse generator (n = 21)
Number of subjects: 44
Study 10705194 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (n = 23)
Number of subjects: 44
Study 9089552 — intervention group
Group type: COMPARATOR
Intervention: CFT performed at various environmental temperatures with a Wet Bulb Globe Test (WBGT) greater than 25 degrees C
Number of subjects: 0
Study 1492007 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 126
Study 1492007 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 126
Study 4041332 — intervention group
Group type: EXPERIMENTAL
Intervention: LA propranolol 160 mg
Number of subjects: 15
Study 4041332 — intervention group
Group type: EXPERIMENTAL
Intervention: LA propranolol 320 mg
Number of subjects: 15
Study 4041332 — intervention group
Group type: EXPERIMENTAL
Intervention: LA propranolol 160 mg and 320 mg
Number of subjects: 15
Study 4041332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31117234 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-based clinical algorithm activated when rScO2 dropped below threshold
Number of subjects: 34
Study 31117234 — intervention group
Group type: COMPARATOR
Intervention: Control group with blind monitoring of rScO2
Number of subjects: 34
Study 27974693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab with concurrent chemotherapy and radiotherapy
Number of subjects: 23
Study 26420450 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based information guide
Number of subjects: 16000
Study 26420450 — intervention group
Group type: COMPARATOR
Intervention: General information about rehabilitation
Number of subjects: 16000
Study 24186878 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 272
Study 24186878 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 272
Study 24186878 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 272
Study 24186878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 272
Study 24186878 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 272
Study 21355923 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive drinkers
Number of subjects: 3694
Study 21355923 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumers
Number of subjects: 3694
Study 21355923 — intervention group
Group type: COMPARATOR
Intervention: Abstainers
Number of subjects: 3694
Study 19966341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 2539
Study 19966341 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted to INR 2.0 to 3.0)
Number of subjects: 2539
Study 19966341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 2539
Study 19966341 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2539
Study 17846332 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed cardiotomy blood (centrifugal washing and lipid filtration)
Number of subjects: 266
Study 17846332 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed cardiotomy blood (control)
Number of subjects: 266
Study 15202794 — intervention group
Group type: EXPERIMENTAL
Intervention: New cardiac troponin I (cTnI) assay (Access AccuTnI, Beckman Coulter)
Number of subjects: 106
Study 11687324 — intervention group
Group type: EXPERIMENTAL
Intervention: Group learning programme
Number of subjects: 121
Study 11687324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 10567779 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg, p.o., once daily)
Number of subjects: 0
Study 10567779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8584455 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina fusiformis (1 g/day for 12 months)
Number of subjects: 87
Study 8584455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 2355813 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study 2355813 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 52
Study 2355813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2355813 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including diltiazem, placebo, and propranolol)
Number of subjects: 52
Study 159068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hafnia A anaesthetic system
Number of subjects: 16
Study 159068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hafnia D anaesthetic system
Number of subjects: 16
Study 31511278 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum-of-care intervention package
Number of subjects: 1490